Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 17.2% in January

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 368,545 shares, a decline of 17.2% from the December 31st total of 445,221 shares. Based on an average daily trading volume, of 234,616 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.5% of the company’s stock are sold short. Currently, 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 234,616 shares, the days-to-cover ratio is presently 1.6 days.

Nautilus Biotechnology Price Performance

NAUT traded up $0.13 during trading on Tuesday, reaching $2.14. 260,242 shares of the stock traded hands, compared to its average volume of 212,063. The stock’s 50-day simple moving average is $2.01 and its two-hundred day simple moving average is $1.38. Nautilus Biotechnology has a fifty-two week low of $0.62 and a fifty-two week high of $2.54. The stock has a market cap of $270.30 million, a price-to-earnings ratio of -4.28 and a beta of 1.49.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC grew its position in Nautilus Biotechnology by 860.0% in the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after acquiring an additional 390,000 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Nautilus Biotechnology in the 2nd quarter valued at $163,000. Callan Family Office LLC acquired a new stake in shares of Nautilus Biotechnology in the 2nd quarter valued at $35,000. Clarius Group LLC boosted its holdings in Nautilus Biotechnology by 22.4% in the second quarter. Clarius Group LLC now owns 1,060,460 shares of the company’s stock worth $769,000 after purchasing an additional 193,874 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in Nautilus Biotechnology by 29.5% during the third quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after buying an additional 30,005 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell” and an average price target of $2.50.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.